ArticleThe journal of liquid biopsy2026
A novel imaging-based approach for large extracellular vesicle detection and prognostic stratification in metastatic breast cancer.
Article in The journal of liquid biopsy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Large extracellular vesicles (LEVs) are membrane-bound extracellular particles released by tumour cells into body fluids. Circulating LEVs carry tumour-associated biomaterials and are more abundant than circulating tumour cells (CTCs), representing a valuable liquid biopsy analyte. We evaluated the RareCyte® CTC platform's ability to identify LEVs in blood smears and explored associations with clinicopathological features in a metastatic breast cancer (MBC) cohort. Methods: MBC patient samples (N = 72) from a previously published prospective comparison study were retrospectively re-analysed to develop and validate an LEV identification and enumeration workflow. Correlations with CellSearch® tumour-derived extracellular vesicle (tdEV) counts and CTC counts were assessed using Spearman's rho. Between-platform comparisons were performed using Wilcoxon's signed-rank test Associations with overall survival (OS) were assessed using Kaplan-Meier analysis and Cox proportional hazards models. Overall survival was defined as the interval between blood collection and death from any cause. Results: Median LEV count [IQR] was 89 [53-208], with detectable LEVs in patients with low or absent CTC counts. LEV counts positively correlated with matched CTC counts (Spearman's ρ = 0.88, p < 0.001) and CellSearch tdEV counts (Spearman's ρ = 0.80, p < 0.001). Higher LEV counts were associated with significantly shorter overall survival (p = 0.04). RareCyte LEV counts were significantly higher than CellSearch tdEV counts, potentially reflecting methodological differences between enrichment workflows. In Cox analysis, higher LEV counts were associated with shorter OS (HR per 100 LEVs = 1.04, p = 0.0015), and CTCs were also significantly associated with OS. Conclusion: We developed an operational workflow for LEV detection and quantification using the RareCyte® CTC analysis platform. The inclusion of LEVs into CTC-based liquid biopsy analyses may provide complementary biomarker information, particularly in patients with low CTC burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.